Head-to-head evidence
DBPR108 vs Vildagliptin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: DPP-4 · full Type 2 Diabetes pipeline
DBPR108
Developed by CSPC Pharmaceutical Group
NCT04161430 · Phase 3 · completed
In this randomized, quadruple-blind, placebo- and active-controlled Phase 3 trial, 766 patients with type 2 diabetes were randomized to DBPR108, sitagliptin, or placebo. DBPR108 reduced HbA1c significantly more than placebo at 24 weeks, with a treatment difference whose confidence interval excluded no effect.
Vildagliptin · Galvus
Developed by Novartis
NCT00099866 · Phase 3 · completed
The study was randomized and double-blind, with an active metformin comparator and 570 participants. Its primary endpoint was the surrogate measure of HbA1c change, and because no trial results are posted, it cannot be determined whether the primary comparison was favorable.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: DBPR108's landscape · Vildagliptin's landscape